Increased coverage for advanced breast cancer patients

The government will increase health insurance benefits for treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes, the Health Ministry announced recently.

To this end, Roche’s Herceptin (trastuzumab) has been selected as the first-line drug from this mon...